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Background: Chronic idiopathic cough (known as cough hypersensitivity syndrome) is defined by cough in the
absence of an identifiable cause. Gabapentin has been suggested as a treatment but evidence is scarce. The aim
of our study was to describe the clinical features of patients with unexplained chronic cough and to investigate
the effect of gabapentin (600 mg twice a day for a minimal duration of 4 weeks) in reducing cough symptoms.
Methods: A patient cohort analysis was performed. Patients were retrieved using a query in our medical
database for the words ‘cough’ and ‘gabapentin’ in 2011. Patients without a clear etiology of cough despite
having performed a stepwise diagnostic approach, were included. Medical records of these patients were analyzed.
A telephonic survey was performed and patients were asked to retrospectivally rate their cough when they
attended the outpatient clinic. They were then asked to rate their cough after treatment with gabapentin.
A scale from one to ten was used to score cough severity. They were also questioned about the triggers inducing
cough. To evaluate the cough severity score, the results were correlated with questions of the Leicester
Cough Questionnaire.
Results: We recruited 51 patients (87% female) with a mean age of onset of 47 years (± 14 y) and an average
cough duration of 48 months. The most frequently reported cough triggers included change of temperature (57%),
talking (49%) and odours (45%). In 67% of patients, the urge to cough was located in the throat area. Thirty-five
patients effectively took the prescribed gabapentin. The average improvement in cough score was 2.8/10
(p<0.0001). Of the 35 patients, 20 achieved improvement of their cough symptoms. Responders had a higher
pre-treatment cough severity score (p=0.02) and were more likely to have a history of pre-cough airway infection
(p=0.04). Current cough severity score negatively correlated with the Leicester Cough Questionnaire scores (p=0.05).
Conclusion: Chronic idiopathic cough were predominantly middle-aged women, frequently reporting various
cough triggers. We also demonstrated that gabapentin can significantly improve cough in these patients.
Responders tend to have higher pre-treatment severity scores and have a history of an airway infection.Background
Chronic cough often remains a diagnostic and therapeutic
challenge. It is associated with a significant impaired qua-
lity of life and health care cost. Current guidelines suggest
the use of both diagnostic tests and empirical treatment
trials in its management [1]. The most common condi-
tions associated with chronic cough are gastro-esophageal
reflux disease, asthma syndromes and upper airway disor-
ders such as rhinitis or rhinosinusitis [2]. A final diagnosis
of chronic idiopathic cough is made when there is no* Correspondence: Pieter.goeminne@student.kuleuven.be
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distribution, and reproduction in any mediumidentifiable cause [3,4]. A universal characteristic of these
patients is an abnormally sensitive cough reflex. Therefore
the term ‘cough hypersensitivity syndrome’ was recently
introduced [5]. The greatest challenge in these patients is
downregulating this cough hypersensitivity. Fortunately,
several novel mechanisms have been identified, which may
lead to the identification of targets that could lead to new
effective antitussives [6]. As pathophysiological mecha-
nisms are thought to be similar between chronic cough
and neuropathic pain, gabapentin was recently tried as a
potential treatment for chronic idiopathic cough [7,8]. In a
randomized, double-blind, placebo-controlled trial, Ryan
et al. show that gabapentin is a well-tolerated therapy thatd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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quency of cough and severity [8].
The aim of this article is to describe the clinical char-
acteristics of the patient cohort with idiopathic cough
seen at our chronic cough outpatient clinic and recent
empirical experience of efficacy of treatment with gaba-
pentin in this population.
Methods
Patients were recruited using a query in our medical
database. The keywords ‘cough’ and ‘gabapentin’ and an
outpatient clinic visit in 2011 were the selection criteria.
All hits were analyzed for presence of chronic idiopathic
cough. We defined idiopathic cough as a cough that
lasted for more than eight weeks in the absence of any
abnormality in the clinical examination, chest radio-
graph, CT sinuses, lung function, negative histamine
provocation test, differential cell count of induced spu-
tum and no pathological reflux during a 24 hours pH/
impedance monitoring. In addition to the diagnostic
work-up, all patients underwent empirical treatment
trials with proton pump inhibitors (≥ 6 weeks of omepra-
zole 40mg twice daily), nasal decongestants, (≥ 6 weeks
fluticasone 100μg twice daily or equivalent) and inhaled
steroids ((≥ 6 weeks fluticasone 250μg twice daily
or equivalent).
Individual files were then analyzed for patient charac-
teristics looking at gender, age of onset, prior upper airway
infections, duration of cough symptoms, smoking habits,
cough triggers and response to trial therapies given.
Patients who did not improve under the previous the-
rapies were put on gabapentin. A minimum therapy
duration of at least four weeks was suggested using an
initial dose of 300 mg for four days, increasing with
300 mg each four days until a maintenance dose was
reached of 600 mg twice daily. Patients needed a treat-
ment period of four weeks or more to be included into
the analysis.
All patients were seen at the outpatient clinic one to
two months later to evaluate therapy. Patients were
asked about the nature and severity of their cough by
means by a pre-set list of questions. We also contacted
all patients using a telephone survey. They were asked
to retrospectively score their cough severity on a scale
of ten before they attended the outpatient clinic. A score
of zero was equal to no cough and a score of ten
was the worst cough possible. Subsequently they were
asked to score their present cough severity (after gaba-
pentin treatment).
To validate this cough severity scale, we also added
four questions of the Leicester Cough Questionnaire [9],
using the Dutch version [10], to correlate these scores
with the cough severity scale. The Leicester Cough
Questionnaire questions asked were: In the last 2 weeks,my cough has interfered with my job, or other daily tasks;
In the last 2 weeks, has your cough disturbed your sleep?;
In the last 2 weeks, how many times a day have you had
coughing bouts?; In the last 2 weeks, my cough has inter-
rupted conversation or telephone call. Each question is
scored from one to seven and a lower score indicates
higher impact of cough on quality of life.
Approval was obtained from the local ethical com-
mittee of UZ Leuven, Belgium and patients were asked
by telephone if the data could be used for anony-
mous analysis.
Results were expressed as mean with standard de-
viation in case of normal distribution or as median with
interquartile range for non-normal data. Paired t-test or
Wilcoxon signed-rank test was used according to distri-
bution of the data as were unpaired t-test and Mann–
Whitney U test. Correlations were analyzed using a
Pearson analysis for parametric data or Spearman’s rank
analysis for non-parametric data. P-values reached sig-
nificance if lower than 0.05 and two-tailed testing was




We collected data from 51 patients. Forty-one (80%)
were female, with a mean age of onset of cough of
47 years (SD ± 14 years). Median duration of chronic
cough before outpatient visit was 48 months (IQR 2 –
192) and 28% had a history of an airway infection.
Patients almost universally complained of a dry, non-
productive cough, with irritation and discomfort loca-
lized in the throat (67%) or in the chest area (33%),
leading to paroxysms of coughing. Diurnal variation
showed daytime predominance in 69% of the population
and nocturnal predominance in 12%.
Strong associations were also seen when triggers of
cough were investigated. Changes in temperature,
mainly transition to cold outside, was a trigger in 57% of
patients. Other triggers such as talking (41%), strong
odors (31%), physical effort (20%) and eating (29%) were
also common (Table 1). Patients pointed out that even a
minimal trigger induced their cough which is indicative
of their increased cough reflex sensitivity.
Effect of gapapentin
Our retrospective analysis showed that 43 patients
effectively took gabapentin. Eight subjects discontinued
during treatment due to adverse effects (fatigue (5) and
dizziness (3)). Another eight subject did not start the
treatment because of a fear of side-effects. Of a total of
35 patients who completed their treatment with gaba-
pentin, a mean reduction in cough severity score of
2.8 was seen (p<0.0001) (Figure 1). Subanalysis showed
Table 1 Triggers of cough: Table showing total number
of patients (and percentage) suffering coughing bouts if
exposed to the specific trigger
Cough triggers N (%)
Temperature change 29 (57%)
Talking 21 (41%)







Figure 2 Comparison of cough severity score before gabapentin
treatment between responders and non-responders: responders
to gabapentin treatment showed significant higher pretreatment
cough severity score (p=0.02).
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20 (57%) of these patients with complete remission
(cough score 0) in two patients. No patient reported an
increase in cough symptoms during their treatment.
We investigated if there were certain characteristics
that predicted response to gabapentin. There was a sig-
nificant difference in pre-treatment cough severity score
between responders and non-responders. Responders
have a higher subjective cough severity score before
the treatment compared to non-responders (p=0.02)
(Figure 2). Patients with a history of an upper airway in-
fection also showed a significant higher improvement
after gabapentin use than the other patients (p=0.04).
There was no difference between responders and non-
responders in terms of age, duration of cough, number
of triggers, reflux or day/night predominance.
Current cough severity score correlated with the ave-
rage of the four Leicester Cough Questionnaire scores,Figure 1 Cough Severity score before and after the start of
gabapentin: A significant improvement is seen of the cough
severity score after start of gabapentin (p<0.0001; 95%
Confidence interval 1.7–3.9).indicating that cough severity score is a reliable tool to
score cough severity (p=0.05; r= −0.28) (Figure 3).
Discussion
Our results suggest that chronic idiopathic cough
patients were predominantly middle-aged women, fre-
quently reporting various cough triggers. Change in
temperature, talking and strong odours are the mostFigure 3 Correlation between cough severity score and
average of the four Leicester Cough Questionnaire scores: a
significant negative correlation was seen between Leicester
Cough Questionnaire and cough severity score (p=0.05;
r= −0.28). Lower scores in the Leicester Cough Questionnaire
signify a higher impact of cough on daily life. LCQ = Leicester
Cough Questionnaire.
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twice daily, might improve cough in patients with chronic
idiopathic cough. Patients were more likely to respond
to gabapentin if they had a history of an airway infection
before the onset of the chronic cough and if they had a
pre-treatment cough severity score higher than eight.
The cough severity score, where patients score their
cough severity on a scale of zero to ten, correlated with
questions from the Leicester Cough Questionnaire.
Our patient characteristics are in line with the results
from Haque et al. They reported that patients with idio-
pathic cough, often had an upper respiratory tract infec-
tion preceding their cough [11]. This was also seen in
our patient cohort. We found that patients with chronic
idiopathic cough were often middle-aged women with a
long history of cough, confirming the distinct clinical
phenotype suggested by Haque et al. and also found in
the recent trial by Ryan and colleagues [8]. Patients
clearly present with a longstanding cough problem. This
is due to the fact that patients often have a long history
of investigations and trial treatments before attending a
tertiary outpatient clinic.
The improvement of cough severity with gabapentin
treatment we see has previously been suggested in case
reports [7] and in the recent randomised, double-blind,
placebo-controlled trial by Ryan et al. [8]. The latter
shows a mean improvement in cough severity of 11.1
mm while we saw a slightly higher improvement of
2.8 (which equals 28 mm). A similar rate of side effects
was seen with fatigue and dizziness in 19%, but with a
lower rate of nausea of 9% in our cohort. This might be
due to the lower maximum dose of gabapentin we used
(1200 mg vs 1800 mg) [8]. We found that a subset
of patients did not benefit from gabapentin treatment.
This reflects the heterogeneity of chronic idiopathic
cough where refractory cough is caused by many disor-
ders [12-15]. The analysis of the cough scores showed
that it is particularly effective in a subgroup of patients
with a high initial cough score and in patients who pre-
viously had an airway infection. Further studies are
warranted to unravel the exact mechanism of action of
gabapentin in chronic idiopathic cough.
The triggers found to be associated with cough in
chronic idiopathic cough patients are more or less in
line with literature where temperature changes, talking,
eating and smoke or fragrances are described as the
most prominent [16]. Patients that responded to the
gabapentin therapy also mentioned that their cough
response to these triggers was decreased. This is in con-
trast with the findings of Ryan et al. who could not show
a significant change in peripheral cough reflex sensitivity,
suggesting that gabapentin did not act by reducing pe-
ripheral sensitisation [8]. In our analysis, the decreased
response to those triggers was a subjective feeling thepatient had following the use of gabapentin, whereas
Ryan et al. used an objective single-dose capsaicin cough
reflex sensitivity method.
There are however limitations to our results. Patients
were asked to recall severity of cough before onset of
treatment and therefore recall bias might influence the
results. We do not think that this will influence the
results much as each patient clearly recalled whether
gabapentin improved their cough. As this was not a
placebo-controlled trial, the effect could also be attribu-
ted to a placebo effect. Nonetheless we have to bear in
mind that these patients previously had multiple other
treatments without any benefit. Subsequently, the major-
ity of them were very reluctant in trying yet ‘another’
treatment. Our uncontrolled, open-label study results
confirm the recent findings of Ryan and colleagues [8].
Conclusion
In conclusion, we show that chronic idiopathic cough
were predominantly middle-aged women and demon-
strated that gabapentin can significantly improve cough
in these patients. Responders tend to have higher pre-
treatment severity scores and have a history of an airway
infection. Further randomized, placebo controlled stu-
dies are warranted to confirm these findings and more
research is needed to unravel the mechanisms by which
gabapentin improves cough.
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